Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diamondback Energy Inc FANG

Diamondback Energy, Inc., together with its subsidiaries, is an independent oil and natural gas company focused on the acquisition, development, exploration and exploitation of unconventional, onshore oil and natural gas reserves primarily in the Permian Basin in West Texas. The Company's activities are primarily directed at the horizontal development of the Wolfcamp and Spraberry formations in the Midland Basin and the Wolfcamp and Bone Spring formations in the Delaware Basin within the Permian Basin. Additionally, its subsidiary, Viper Energy, Inc., is focused on owning and acquiring mineral interests and royalty interests in oil and natural gas properties primarily in the Permian Basin. It has approximately 870,303 net acres, which primarily consisted of approximately 715,956 net acres in the Midland Basin and 154,026 net acres in the Delaware Basin. The Company's subsidiaries include Diamondback E&P LLC, Rattler Midstream GP LLC, Rattler Midstream LP, and QEP Resources, Inc.


NDAQ:FANG - Post by User

Post by LeaMileson Apr 18, 2022 2:48am
187 Views
Post# 34609156

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
Bullboard Posts
Next >>